Home » Stocks » Sesen Bio

Sesen Bio, Inc. (SESN)

Stock Price: $1.06 USD 0.02 (1.92%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 117.04M
Revenue (ttm) n/a
Net Income (ttm) -59.46M
Shares Out 110.42M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $1.06
Previous Close $1.04
Change ($) 0.02
Change (%) 1.92%
Day's Open 1.09
Day's Range 1.02 - 1.09
Day's Volume 9,650,366
52-Week Range 0.37 - 1.54

More Stats

Market Cap 117.04M
Enterprise Value 74.56M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 110.42M
Float 106.34M
EPS (basic) -0.82
EPS (diluted) -0.68
FCF / Share -0.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.73M
Short Ratio 2.88
Short % of Float 1.40%
Beta 1.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.98
Revenue n/a
Operating Income -41.45M
Net Income -59.46M
Free Cash Flow -38.50M
Net Cash 42.48M
Net Cash / Share 0.38
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -24.66%
ROE -210.42%
ROIC 1,306.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(222.64% upside)
Current: $1.06
Target: 3.42
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth---98.58%2928.38%-55.86%68.14%---
Gross Profit--0.4329.980.992.241.33--
Operating Income-36.87-25.70-20.161.77-35.20-32.93-16.48-19.48-12.68
Net Income-108-33.69-29.031.89-33.45-34.16-18.03-19.66-12.83
Shares Outstanding90.9361.7726.1121.0818.9914.641.350.990.80
Earnings Per Share-1.18-0.55-1.110.09-1.76-2.37-16.18-22.93-17.80
Operating Cash Flow-37.52-22.83-17.772.54-34.53-29.31-13.49-19.09-10.87
Capital Expenditures-0.14-0.100.33-0.29-0.14--0.11-0.81
Free Cash Flow-37.66-22.83-17.672.86-34.82-29.44-13.49-19.20-11.67
Cash & Equivalents48.1450.4414.6925.3536.1754.
Total Debt----13.9010.004.522.011.03
Net Cash / Debt48.1450.4414.6925.3522.2844.153.526.01-0.20
Book Value-26.7044.2118.0338.6818.9436.83-54.33-39.30-19.79
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sesen Bio, Inc.
Country United States
Employees 25
CEO Thomas R. Cannell

Stock Information

Ticker Symbol SESN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SESN
IPO Date February 6, 2014


Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.